Biotech is entering a new era of mega blockbusters - drugs with peak sales potential exceeding $10 billion. Drug developers are increasingly focusing on novel therapies that can reach the largest possible patient populations. While obesity is on the verge of becoming the largest therapeutic area in the history of the pharmaceutical industry, the trend of developing broadly impactful medicines is expected to accelerate. However, the implications of the Inflation Reduction Act (IRA) introduce uncertainty about how extensively pharma and biotech can ultimately reach as many patients as possible. Session attendees will hear from industry experts as they discuss the current shift toward prioritizing larger indications early in development, and the implications of less incentive to pursue smaller indications later in a drug's lifecycle.